{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:39:27Z","timestamp":1790127567162,"version":"4.0.1"},"reference-count":40,"publisher":"e-Century Publishing Corporation","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/eafu3015","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T01:21:52Z","timestamp":1735608112000},"page":"7317-7329","source":"Crossref","is-referenced-by-count":5,"title":["NOTCH1 regulates the DNA damage response and sorafenib resistance by activating ATM in hepatocellular carcinoma"],"prefix":"10.62347","volume":"16","author":[{"given":"Jing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G and Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.","journal-title":"Cancer Res"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1053\/j.seminoncol.2012.05.005","article-title":"Molecular targeted therapies in hepatocellular carcinoma","volume":"39","author":"Tanaka","year":"2012","unstructured":"Tanaka S and Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol 2012; 39: 486-492.","journal-title":"Semin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z. Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jhep.2012.02.019","article-title":"Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells","volume":"57","author":"Blivet-Van Eggelpoel","year":"2012","unstructured":"Blivet-Van Eggelpoel MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, Priam S, Housset C, Rosmorduc O and Desbois-Mouthon C. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 2012; 57: 108-115.","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1741-7015-7-41","article-title":"Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study","volume":"7","author":"Zhang","year":"2009","unstructured":"Zhang Z, Zhou X, Shen H, Wang D and Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 2009; 7: 41.","journal-title":"BMC Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2147\/JHC.S285726","article-title":"Elucidating the molecular basis of sorafenib resistance in HCC: current findings and future directions","volume":"8","author":"Fornari","year":"2021","unstructured":"Fornari F, Giovannini C, Piscaglia F and Gramantieri L. Elucidating the molecular basis of sorafenib resistance in HCC: current findings and future directions. J Hepatocell Carcinoma 2021; 8: 741-757.","journal-title":"J Hepatocell Carcinoma"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.3390\/ijms24032805","article-title":"The roles of epigenetic regulation and the tumor microenvironment in the mechanism of resistance to systemic therapy in hepatocellular carcinoma","volume":"24","author":"Oura","year":"2023","unstructured":"Oura K, Morishita A, Hamaya S, Fujita K and Masaki T. The roles of epigenetic regulation and the tumor microenvironment in the mechanism of resistance to systemic therapy in hepatocellular carcinoma. Int J Mol Sci 2023; 24: 2805.","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"105820","DOI":"10.1016\/j.biocel.2020.105820","article-title":"Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells","volume":"126","author":"Liu","year":"2020","unstructured":"Liu J, Yang X, Liang Q, Yu Y, Shen X and Sun G. Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells. Int J Biochem Cell Biol 2020; 126: 105820.","journal-title":"Int J Biochem Cell Biol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1432-0436.2008.00288.x","article-title":"The Notch pathway in prostate development and cancer","volume":"76","author":"Leong","year":"2008","unstructured":"Leong KG and Gao WQ. The Notch pathway in prostate development and cancer. Differentiation 2008; 76: 699-716.","journal-title":"Differentiation"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","unstructured":"Weng AP, Ferrando AA, Lee W, Morris JP 4th, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT and Aster JC. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.","journal-title":"Science"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Yuan X, Zhang M, Wu H, Xu H, Han N, Chu Q, Yu S, Chen Y and Wu K. Expression of Notch1 correlates with breast cancer progression and prognosis. PLoS One 2015; 10: e0131689.","DOI":"10.1371\/journal.pone.0131689"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41585-018-0005-1","article-title":"Unravelling disparate roles of NOTCH in bladder cancer","volume":"15","author":"Goriki","year":"2018","unstructured":"Goriki A, Seiler R, Wyatt AW, Contreras-Sanz A, Bhat A, Matsubara A, Hayashi T and Black PC. Unravelling disparate roles of NOTCH in bladder cancer. Nat Rev Urol 2018; 15: 345-357.","journal-title":"Nat Rev Urol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.3390\/cells9122677","article-title":"NOTCH1 signaling in head and neck squamous cell carcinoma","volume":"9","author":"Shah","year":"2020","unstructured":"Shah PA, Huang C, Li Q, Kazi SA, Byers LA, Wang J, Johnson FM and Frederick MJ. NOTCH1 signaling in head and neck squamous cell carcinoma. Cells 2020; 9: 2677.","journal-title":"Cells"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.celrep.2016.07.038","article-title":"NOTCH1 inhibits activation of ATM by impairing the formation of an ATM-FOXO3a-KAT5\/Tip60 complex","volume":"16","author":"Adamowicz","year":"2016","unstructured":"Adamowicz M, Vermezovic J and d’Adda di Fagagna F. NOTCH1 inhibits activation of ATM by impairing the formation of an ATM-FOXO3a-KAT5\/Tip60 complex. Cell Rep 2016; 16: 2068-2076.","journal-title":"Cell Rep"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrm3546","article-title":"The ATM protein kinase: regulating the cellular response to genotoxic stress, and more","volume":"14","author":"Shiloh","year":"2013","unstructured":"Shiloh Y and Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 2013; 14: 197-210.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrm3719","article-title":"Double-strand break repair: 53BP1 comes into focus","volume":"15","author":"Panier","year":"2014","unstructured":"Panier S and Boulton SJ. Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol 2014; 15: 7-18.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00412-008-0154-8","article-title":"Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network","volume":"117","author":"Greenberg","year":"2008","unstructured":"Greenberg RA. Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network. Chromosoma 2008; 117: 305-317.","journal-title":"Chromosoma"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"120976","DOI":"10.1016\/j.lfs.2022.120976","article-title":"Valproic acid regulates MIEF1 through MST2-HIPPO to suppress breast cancer growth","volume":"309","author":"Du","year":"2022","unstructured":"Du S, Wang X, Hu Y, Zhang S, Wang D, Zhang Q and Liu S. Valproic acid regulates MIEF1 through MST2-HIPPO to suppress breast cancer growth. Life Sci 2022; 309: 120976.","journal-title":"Life Sci"},{"key":"ref18","unstructured":"Kalantar H, Rashidi M, Kalantar M, Tavallaei M and Hosseini SM. Anticancer effects of valproic acid via regulation of epigenetic mechanisms in non-small-cell lung cancer A549 cell line. Iran J Pharm Res 2021; 20: 133-140."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/febs.15122","article-title":"Valproic acid targets HDAC1\/2 and HDAC1\/PTEN\/Akt signalling to inhibit cell proliferation via the induction of autophagy in gastric cancer","volume":"287","author":"Sun","year":"2020","unstructured":"Sun J, Piao J, Li N, Yang Y, Kim KY and Lin Z. Valproic acid targets HDAC1\/2 and HDAC1\/PTEN\/Akt signalling to inhibit cell proliferation via the induction of autophagy in gastric cancer. FEBS J 2020; 287: 2118-2133.","journal-title":"FEBS J"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"MI","year":"2014","unstructured":"Love MI, Huber W and Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.","journal-title":"Genome Biol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4103\/0974-7788.76794","article-title":"Understanding survival analysis: kaplan-meier estimate","volume":"1","author":"MK","year":"2010","unstructured":"Goel MK, Khanna P and Kishore J. Understanding survival analysis: kaplan-meier estimate. Int J Ayurveda Res 2010; 1: 274-278.","journal-title":"Int J Ayurveda Res"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Katoh M and Katoh M. Precision medicine for human cancers with Notch signaling dysregulation (Review). Int J Mol Med 2020; 45: 279-297.","DOI":"10.3892\/ijmm.2019.4418"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3390\/ijms22031325","article-title":"Relevance of notch signaling for bone metabolism and regeneration","volume":"22","author":"Ballhause","year":"2021","unstructured":"Ballhause TM, Jiang S, Baranowsky A, Brandt S, Mertens PR, Frosch KH, Yorgan T and Keller J. Relevance of notch signaling for bone metabolism and regeneration. Int J Mol Sci 2021; 22: 1325.","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2011.12.025","article-title":"Use of the gamma-H2AX assay to monitor DNA damage and repair in translational cancer research","volume":"327","author":"Ivashkevich","year":"2012","unstructured":"Ivashkevich A, Redon CE, Nakamura AJ, Martin RF and Martin OA. Use of the gamma-H2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett 2012; 327: 123-133.","journal-title":"Cancer Lett"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s00259-022-05974-8","article-title":"Individual radiosensitivity reflected by gamma-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy","volume":"50","author":"Widjaja","year":"2023","unstructured":"Widjaja L, Werner RA, Krischke E, Christiansen H, Bengel FM, Bogdanova N and Derlin T. Individual radiosensitivity reflected by gamma-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy. Eur J Nucl Med Mol Imaging 2023; 50: 602-612.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nsmb.3013","article-title":"Notch is a direct negative regulator of the DNA-damage response","volume":"22","author":"Vermezovic","year":"2015","unstructured":"Vermezovic J, Adamowicz M, Santarpia L, Rustighi A, Forcato M, Lucano C, Massimiliano L, Costanzo V, Bicciato S, Del Sal G and d’Adda di Fagagna F. Notch is a direct negative regulator of the DNA-damage response. Nat Struct Mol Biol 2015; 22: 417-424.","journal-title":"Nat Struct Mol Biol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"188493","DOI":"10.1016\/j.bbcan.2020.188493","article-title":"The role of DNA damage and repair in liver cancer","volume":"1875","author":"Gillman","year":"2021","unstructured":"Gillman R, Lopes Floro K, Wankell M and Hebbard L. The role of DNA damage and repair in liver cancer. Biochim Biophys Acta Rev Cancer 2021; 1875: 188493.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"de Almeida LC, Calil FA, Machado-Neto JA and Costa-Lotufo LV. DNA damaging agents and DNA repair: from carcinogenesis to cancer therapy. Cancer Genet 2021; 252-253: 6-24.","DOI":"10.1016\/j.cancergen.2020.12.002"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pilie","year":"2019","unstructured":"Pilie PG, Tang C, Mills GB and Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 2019; 16: 81-104.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O&#x2019","year":"2015","unstructured":"O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell 2015; 60: 547-560.","journal-title":"Mol Cell"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1038\/s41388-022-02384-w","article-title":"A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers","volume":"41","author":"KS","year":"2022","unstructured":"Oh KS, Nam AR, Bang JH, Seo HR, Kim JM, Yoon J, Kim TY and Oh DY. A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers. Oncogene 2022; 41: 3939-3952.","journal-title":"Oncogene"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12967-023-04015-8","article-title":"Valproic acid inhibits cell growth in both MCF-7 and MDA-MB231 cells by triggering different responses in a cell type-specific manner","volume":"21","author":"Giordano","year":"2023","unstructured":"Giordano F, Paoli A, Forastiero M, Marsico S, De Amicis F, Marrelli M, Naimo GD, Mauro L and Panno ML. Valproic acid inhibits cell growth in both MCF-7 and MDA-MB231 cells by triggering different responses in a cell type-specific manner. J Transl Med 2023; 21: 165.","journal-title":"J Transl Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s40618-023-02092-6","article-title":"Valproic acid radiosensitizes anaplastic thyroid cells through a decrease of the DNA damage repair capacity","volume":"46","author":"Perona","year":"2023","unstructured":"Perona M, Ibanez IL, Thomasz L, Villaverde MS, Oglio R, Rosemblit C, Grissi C, Campos-Haedo M, Dagrosa MA, Cremaschi G, Duran HA and Juvenal GJ. Valproic acid radiosensitizes anaplastic thyroid cells through a decrease of the DNA damage repair capacity. J Endocrinol Invest 2023; 46: 2353-2365.","journal-title":"J Endocrinol Invest"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/genes14061295","article-title":"Histone deacetylases (HDAC) inhibitor-valproic acid sensitizes human melanoma cells to dacarbazine and PARP inhibitor","volume":"14","author":"Drzewiecka","year":"2023","unstructured":"Drzewiecka M, Gajos-Michniewicz A, Hoser G, Jasniak D, Barszczewska-Pietraszek G, Sitarek P, Czarny P, Piekarski J, Radek M, Czyz M, Skorski T and Sliwinski T. Histone deacetylases (HDAC) inhibitor-valproic acid sensitizes human melanoma cells to dacarbazine and PARP inhibitor. Genes (Basel) 2023; 14: 1295.","journal-title":"Genes (Basel)"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","article-title":"Playing the end game: DNA double-strand break repair pathway choice","volume":"47","author":"JR","year":"2012","unstructured":"Chapman JR, Taylor MR and Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell 2012; 47: 497-510.","journal-title":"Mol Cell"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1158\/0008-5472.CAN-22-2233","article-title":"NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer","volume":"83","author":"Xie","year":"2023","unstructured":"Xie R, Cheng L, Huang M, Huang L, Chen Z, Zhang Q, Li H, Lu J, Wang H, Zhou Q, Huang J, Chen X and Lin T. NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer. Cancer Res 2023; 83: 1666-1683.","journal-title":"Cancer Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cancers11010016","article-title":"Mifepristone overcomes tumor resistance to temozolomide associated with DNA damage repair and apoptosis in an orthotopic model of glioblastoma","volume":"11","author":"Llaguno-Munive","year":"2018","unstructured":"Llaguno-Munive M, Romero-Pina M, Serrano-Bello J, Medina LA, Uribe-Uribe N, Salazar AM, Rodriguez-Dorantes M and Garcia-Lopez P. Mifepristone overcomes tumor resistance to temozolomide associated with DNA damage repair and apoptosis in an orthotopic model of glioblastoma. Cancers (Basel) 2018; 11: 16.","journal-title":"Cancers (Basel)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"188597","DOI":"10.1016\/j.bbcan.2021.188597","article-title":"Inhibiting homologous recombination by targeting RAD51 protein","volume":"1876","author":"Demeyer","year":"2021","unstructured":"Demeyer A, Benhelli-Mokrani H, Chenais B, Weigel P and Fleury F. Inhibiting homologous recombination by targeting RAD51 protein. Biochim Biophys Acta Rev Cancer 2021; 1876: 188597.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"107492","DOI":"10.1016\/j.pharmthera.2020.107492","article-title":"Role of Rad51 and DNA repair in cancer: a molecular perspective","volume":"208","author":"Laurini","year":"2020","unstructured":"Laurini E, Marson D, Fermeglia A, Aulic S, Fermeglia M and Pricl S. Role of Rad51 and DNA repair in cancer: a molecular perspective. Pharmacol Ther 2020; 208: 107492.","journal-title":"Pharmacol Ther"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/12\/ajtr0157995.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:51:16Z","timestamp":1766022676000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/12\/ajtr0157995.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/eafu3015","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}